Ulf Jönsson to become Chief Executive Officer of Biacore International AB

Ulf Jönsson to become Chief Executive Officer of Biacore International AB Lars-Göran Andrén to take up the Position of Non Executive Chairman Uppsala, Sweden, 21st November, 2001. The Board of Biacore International AB is pleased to announce the appointment of Dr Ulf Jönsson, the Company's President, as Chief Executive Officer effective 1st January 2002. Dr Jönsson will assume the position of CEO from Lars-Göran Andrén, Biacore's current Chairman and CEO. This is as a result of Mr. Andrén's need, for health reasons, to play a less active role in Biacore's development on a day-to-day basis. Mr. Andrén, who has been the driving force behind Biacore's success over the last nine years, will take early retirement from his current position and become the Company's Non- Executive Chairman as of 1st January 2002. The Board has decided, in line with Mr Andrén's contract, to compensate him for his early retirement. The total remaining cost for Mr Andrén´s future pension calculated up to a maximum of SEK 13 million, will be taken as a charge in the fourth quarter of the current financial year. Commenting on today's announcement Donald R. Parfet, Biacore's Deputy Chairman said " I would like to thank Lars-Göran for the enormous contribution that he has made to Biacore's success over the last nine years, a period that has seen the Company become the global leading provider of SPR technology, a technology that is dramatically improving the economics of drug discovery and development at pharmaceutical and biotechnology companies and prestigious life science research institutes around the world". Notes to Editors: About Biacore Biacore is a global market leader in Surface Plasmon Resonance (SPR) based technology with its own sales operations in the U.S., across Europe, in Japan, Australia and New Zealand. The technology is protected by a strong patent portfolio. Target groups consist primarily of medical and life science research laboratories and pharmaceutical and biotechnology companies all over the world. Biacore focuses on drug discovery as the prime area for future growth. The Company currently has seven systems on the market with its Biacore®S51 for applications downstream of high-throughput screening (HTS) including rapid characterization of HTS hits and comprehensive preclinical evaluation of lead compounds. Biacore®3000 offers specific applications in drug discovery upstream of HTS. A new SPR array system is currently under development. Based in Uppsala, Sweden, the Company is listed on Stockholmsbörsen and Nasdaq in the U.S. In 2000 the Company had sales of SEK 438.8 million and an operating income of SEK 78.0 million. Further information on Biacore can be found on the web: www.biacore.com Address and phone: Biacore International AB Rapsgatan 7, SE-754 50 Uppsala, SWEDEN Phone: +46 (0)18-675700 Fax: +46 (0)18-150110 info@biacore.com ------------------------------------------------------------ This information was brought to you by Waymaker http://www.waymaker.net The following files are available for download: http://www.waymaker.net/bitonline/2001/11/21/20011121BIT00710/bit0002.doc http://www.waymaker.net/bitonline/2001/11/21/20011121BIT00710/bit0002.pdf

About Us

Biacore™ systems for label-free interaction analysis generate unique data on molecular interactions, giving insights into biological functions and disease mechanisms, and facilitating efficient therapeutic development. Application areas include drug discovery, general life science research, antibody characterization, immunogenicity, biotherapeutic development and manufacture. Biacore AB is a GE Healthcare company. Further information: www.biacore.com